Literature DB >> 1735360

Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats.

K Miyasaka1, A Funakoshi, A Jimi, R Nakamura, M Matsumoto, K Kitani.   

Abstract

The changes in plasma and duodenal cholecystokinin (CCK) concentrations after pancreatic duct occlusion were examined in rats. The rats were sacrificed 1, 3, 7, 10, 14, and 30 days after occlusion of the duct. Histological examination showed acute inflammation on days 1 and 3 after duct occlusion, interstitial fibrosis and regenerative changes on days 7, 10, and 14, and pancreatic atrophy on day 30. The plasma CCK concentration increased from 0.45 pM to 2.0 pM after the occlusion and then remained high throughout the observation period. In contrast to the stable increase in plasma CCK concentration, the CCK content in the duodenum increased on days 1 and 3, decreased on day 7, increased on day 10, reaching over the control level on day 14, and then returned to the control level on day 30. Administration of boiled and 10-fold concentrated rat pancreatic juice or human pancreatic secretory trypsin inhibitor for seven days after pancreatic duct occlusion reversed the decrease in duodenal CCK content. The major molecular forms of duodenal CCK were CCK-8, -33, and -58. These results indicate that (1) basal plasma CCK concentration did not reflect the duodenal CCK content, (2) duodenal CCK content was well correlated with a decrease in inflammation in the pancreas, and (3) a nonenzymatic component in the pancreatic juice reversed the decrease in duodenal CCK content and body weight caused by pancreatic duct occlusion.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735360     DOI: 10.1007/bf01307730

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  41 in total

1.  Effects of intestinal amylase and trypsin on pancreatic secretion in the pig.

Authors:  I Ihse; P Lilja
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

2.  Expression and excretion of human pancreatic secretory trypsin inhibitor in lipoprotein-deletion mutant of Escherichia coli.

Authors:  T Kanamori; S Mizushima; Y Shimizu; H Morishita; H Kubota; A Nii; H Ogino; Y Nagase; M Kisaragi; M Nobuhara
Journal:  Gene       Date:  1988-06-30       Impact factor: 3.688

3.  Plasma concentrations of cholecystokinin, CCK-8, and CCK-33, 39 in rats, determined by a method based on enzyme digestion of gastrin before HPLC and RIA detection of CCK.

Authors:  A Lindén; M Carlquist; S Hansen; K Uvnäs-Moberg
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

4.  Plasma cholecystokinin levels in patients with chronic pancreatitis.

Authors:  A Schafmayer; H D Becker; M Werner; U R Fölsch; W Creutzfeldt
Journal:  Digestion       Date:  1985       Impact factor: 3.216

5.  Elevated plasma cholecystokinin concentrations in exocrine pancreatic atrophy in the rat.

Authors:  U R Fölsch; A Schafmayer; R Ebert; H D Becker; W Creutzfeldt
Journal:  Digestion       Date:  1984       Impact factor: 3.216

6.  Stimulatory effect of monitor peptide and human pancreatic secretory trypsin inhibitor on pancreatic secretion and cholecystokinin release in conscious rats.

Authors:  K Miyasaka; R Nakamura; A Funakoshi; K Kitani
Journal:  Pancreas       Date:  1989       Impact factor: 3.327

7.  Endogenous CCK release and pancreatic growth in rats after feeding a proteinase inhibitor (camostate).

Authors:  B Göke; H Printz; I Koop; U Rausch; G Richter; R Arnold; G Adler
Journal:  Pancreas       Date:  1986       Impact factor: 3.327

8.  Short-term inhibition of duodenal tryptic activity does not affect human pancreatic, biliary, or gastric function.

Authors:  J Hotz; S B Ho; V L Go; E P DiMagno
Journal:  J Lab Clin Med       Date:  1983-03

9.  Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol.

Authors:  R A Liddle; I D Goldfine; J A Williams
Journal:  Gastroenterology       Date:  1984-09       Impact factor: 22.682

10.  Low plasma cholecystokinin response after ingestion of a test meal in patients with chronic pancreatitis.

Authors:  A Funakoshi; I Nakano; H Shinozaki; H Ibayashi; K Tateishi; T Hamaoka
Journal:  Am J Gastroenterol       Date:  1985-12       Impact factor: 10.864

View more
  5 in total

1.  Regulation of intestinal concentration of cholecystokinin by bile and/or pancreatic juice.

Authors:  K Miyasaka; A Funakoshi; M Matsumoto; K Kitani
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

2.  Gastrin-releasing peptide and CCK after intraduodenal inhibition of proteases in dogs.

Authors:  R Nustede; W E Schmidt; M Jäger; F Stöckmann; H Köhler; U R Fölsch; H J Peiper
Journal:  Int J Pancreatol       Date:  1994-06

3.  Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.

Authors:  N Sazaki; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

4.  Changes in gene expression of cholecystokinin-A receptor after induction of pancreatitis by pancreatic duct occlusion in rats.

Authors:  K Miyasaka; A Funakoshi
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

5.  Effect of a new cholecystokinin antagonist (FK 480) on gene expression of cholecystokinin and secretin in rat intestine.

Authors:  A Funakoshi; K Miyasaka
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.